Current Report Filing (8-k)
March 18 2019 - 6:09AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): March 14, 2019
SOLENO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36593
|
|
77-0523891
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File No.)
|
|
(IRS Employer
Identification Number)
|
1235 Radio Road, Suite 110
Redwood City, CA 94065
(Address of principal executive offices)
(650)
213-8444
(Registrants telephone number, including area code)
Check the appropriate box below if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§240.12b-2
of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section13(a) of the Exchange Act. ☐
Other Events.
On March 14, 2019,
Soleno Therapeutics, Inc., a Delaware corporation (the Company), issued a press release regarding the Data Safety Monitoring Boards recommendation of the continuation of the Companys Phase III trial in Prader-Willi Syndrome
(PWS) patients, DESTINY PWS, without any changes. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form
8-K.
Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
SOLENO THERAPEUTICS, INC.
|
|
|
|
Date: March 15, 2019
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Anish Bhatnagar
|
|
|
|
|
|
|
Anish Bhatnagar
|
|
|
|
|
|
|
Chief Executive Officer
|
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Soleno Therapeutics (NASDAQ:SLNO)
Historical Stock Chart
From Apr 2023 to Apr 2024